Date:8/21/2008

ar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.

(1) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and

Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress,

Lyon, 2004. Available at: http://www-dep.iarc.fr. Accessed May 2008.

(2) 2005 Cancer Register System (CRS) annual report,

http://crs.cph.ntu.edu.tw/crs_c/annual.html. Accessed May 12, 2008.

(3) Del Pozo AC, Lopez P. Management of hepatocellular carcinoma. Clin

Liver Dis 2007 May;11(2):305-21.

'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCarePharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
2. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
6. Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
7. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
8. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
9. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals